XML 19 R6.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Dec. 31, 2022
Cash flows used in operating activities:        
Net loss $ (3,261) $ (4,805) $ (13,316) $ (20,275)
Adjustments to reconcile net loss to net cash used in operating activities:        
Depreciation and amortization 155 158 628 619
Amortization of deferred financing costs and debt discount 16 66 190 389
Common stock issued for research and development     75 0
Change in fair value of liability instruments     0 (1)
Share-based compensation expense 146 140 569 606
Accretion of discount on short-term investments 1      
Reduction in the carrying amount of operating lease right-of-use assets 31 29 117 93
Loss on disposal of property and equipment   2 2 0
Increases (decreases) in cash caused by changes in operating assets and liabilities:        
Other current assets 150 2,791    
Other assets     2,397 (2,369)
Accounts payable and accrued expenses (43) (3,639) (3,677) 6,452
Change in operating lease liabilities (31) (29) (117) (129)
Deferred grant liability (1,677) (506) 281 1,643
Net cash used in operating activities (4,513) (5,793) (12,851) (12,972)
Cash flows used in investing activities:        
Purchases of property and equipment and intangible assets     (160) (509)
In process research and development acquired     0 (250)
Purchases of property and equipment (40) (97)    
Purchase of short-term investments (324)      
Net cash used in investing activities (364) (97) (160) (759)
Cash flows used in/provided by financing activities:        
Principal payments of term loan obligation (402) (402) (1,608) (1,608)
Purchase of treasury stock (374)   (126) 0
Proceeds from sale of common stock, net   895 5,527 15,832
Payment of offering costs related to sale of common stock     (348) (773)
Net cash (used in) provided by financing activities (776) 493 3,445 13,451
Net decrease in cash and cash equivalents (5,653) (5,397) (9,566) (280)
Cash and cash equivalents at beginning of period 8,554 18,120 18,120 18,400
Cash and cash equivalents at end of period 2,901 12,723 8,554 18,120
Cash paid during period for:        
Interest 23 73 222 327
Supplemental schedule of non-cash investing and financing activities:        
Unpaid offering cost $ 141 25 174 0
Common stock issued in payment for in process research and development     75 0
Right-of-use assets acquired by assuming operating lease liabilities     $ 71 $ 0
Right-of-use assets obtained in exchange for operating lease liability   $ 51